Literature DB >> 15644127

Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections.

I M El-Kady1, M Lotfy, G Badra, S El-Masry, I Waked.   

Abstract

Schistosoma mansoni infection is characterized by a strong T-helper type 2 (Th2) cell-associated immune response, but in the case of viral infection, it is associated with interferon-gamma (IFN-gamma) increase and induction of Th1 immune response. Few data are available about the immune response of cases infected with combined hepatitis C virus (HCV) and schistosomiasis. Thus, the investigation of the cytokine pattern in patients coinfected with both HCV and Schistosoma mansoni was our rationale. This study included four patient groups: Group 1 included 20 patients infected with chronic HCV, Group 2 included 15 patients infected with schistosomiasis alone, Group 3 included 20 patients with chronic HCV and schistosomiasis and Group 4 included 15 healthy control individuals with matched age and sex. Serum levels of IFN-gamma, interleukin (IL)-4, IL-10 and IL-18 were measured in all groups by enzyme-linked immunosorbent assay. The results showed that the patients infected with HCV had significantly higher serum levels of IFN-gamma and IL-18 compared with the controls and with the patients with schistosomiasis and coinfection (P < 0.001). On the other hand, serum levels of IL-4 and IL-10 were significantly higher in patients with schistosomiasis and coinfection compared with the control group (P < 0.001 and 0.0001, respectively) and with the HCV patients (P < 0.05 and P < 0.001, respectively). A significant increase in serum levels of IL-4 and IL-10 was also found in HCV patients compared with the control (P < 0.05). Schistosomiasis appears to induce a Th2 cytokine profile, with increase in serum levels of IL-4 and IL-10, even in the presence of HCV coinfection. In conclusion, schistosomiasis may downregulate the stimulatory effect of HCV on Th1 cytokines and this may lead to the chronicity of HCV infection in coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644127     DOI: 10.1111/j.0300-9475.2005.01529.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.

Authors:  M F Derbala; S R Al Kaabi; N Z El Dweik; F Pasic; M T Butt; R Yakoob; A Al-Marri; A M Amer; N Morad; A Bener
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

2.  Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression.

Authors:  Steven K Lundy; Nicholas W Lukacs
Journal:  Front Immunol       Date:  2013-02-20       Impact factor: 7.561

Review 3.  Schistosome: its benefit and harm in patients suffering from concomitant diseases.

Authors:  Yoshio Osada; Tamotsu Kanazawa
Journal:  J Biomed Biotechnol       Date:  2011-11-03

Review 4.  Interaction Between the Neglected Tropical Disease Human Schistosomiasis and HCV Infection in Egypt: a Puzzling Relationship.

Authors:  Mahmoud M Bahgat
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

5.  Analytical assessment of interleukin - 23 and -27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a).

Authors:  Asghar Ashrafi Hafez; Abbas Ahmadi Vasmehjani; Rasoul Baharlou; Seyed Dawood Mousavi Nasab; Mohammad Hasan Davami; Ahmad Najafi; Negar Joharinia; Hasan Rezanezhad; Nayeb Ali Ahmadi; Masoumeh Imanzad
Journal:  Hepat Mon       Date:  2014-09-27       Impact factor: 0.660

Review 6.  Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses.

Authors:  Alice H Costain; Andrew S MacDonald; Hermelijn H Smits
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

7.  Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.

Authors:  Fengmin Zhou; Amanda Goodsell; Yasushi Uematsu; Michael Vajdy
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

8.  Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.

Authors:  Amal Abdul-rasheed El-Moamly; Mohamed Aly El-Sweify; Rafiaa M Rashad; Esam M Abdalla; Mostafa M Ragheb; Mohamed M Awad
Journal:  Parasitol Res       Date:  2013-03-21       Impact factor: 2.383

9.  Diagnosing schistosomiasis by detection of cell-free parasite DNA in human plasma.

Authors:  Dominic Wichmann; Marcus Panning; Thomas Quack; Stefanie Kramme; Gerd-Dieter Burchard; Christoph Grevelding; Christian Drosten
Journal:  PLoS Negl Trop Dis       Date:  2009-04-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.